A Phase 1/2 Open-label Study to Evaluate The Safety, Tolerability, Efficacy And Pharmacokinetics of Mirvetuximab Soravtansine (TAK-853) in Japanese Patients With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Mirvetuximab soravtansine (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
Most Recent Events
- 20 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 27 May 2024 Status changed from not yet recruiting to recruiting.
- 06 May 2024 New trial record